Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BGF MDI HFO vs HFA in Healthy Volunteers
NCT06340581Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration at Day 2 and Maximum Observed Concentration at Day 2. Planned start Oct 2024; status: withdrawn.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06340581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340581.